Neurol. pro Praxi, 2006; 5: 266-268

Dávkování valproátu a jeho vztah k teratogenicitě

MUDr. Martin Tomášek, MUDr. Petr Marusič
Neurologická klinika 2. LF UK a FN Motol, Praha

Ačkoli se obvyklá účinná dávka valproátu pohybuje v širokém rozmezí mezi 500–2500 mg/den, v klinické praxi je mnoho pacientů kompenzováno na dávkách do 1000 mg/den, zejména těch trpících generalizovanými záchvaty. Z provedeného dotazníkového průzkumu vyplývá, že 1000 mg/den je i průměrná dávka valproátu používaná v ČR při léčbě pacientů se záchvaty parciálními a/nebo sekundárně generalizovanými. Data dostupná v současné době z těhotenských registrů naznačují, že riziko teratogenního vlivu valproátu je na dávce závislé a významně se zvyšuje při použití denních dávek nad 1000–1100 mg/den.

Keywords: epilepsie, valproát, teratogenicita

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomášek M, Marusič P. Dávkování valproátu a jeho vztah k teratogenicitě. Neurol. praxi. 2006;7(5):266-268.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adab N et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75 (11): 1575-1583. Go to original source... Go to PubMed...
    2. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurol 2005; 64 (6): 955-960. Go to original source... Go to PubMed...
    3. Dickinson RG et al. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit 1989; 11 (2): 127-133. Go to original source... Go to PubMed...
    4. Guberman ABJ. Special Management Considerations In: Essentials of Clinical Epilepsy. Butterworth-Heinemann 1999: 156-157.
    5. Morrow J et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77 (2): 93-198. Go to original source... Go to PubMed...
    6. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16 (10): 695-714. Go to original source... Go to PubMed...
    7. Vajda FJE et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 2006; 13 (6): 645-654. Go to original source... Go to PubMed...
    8. Vajda FJE, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005; 112 (3): 137-143. Go to original source... Go to PubMed...
    9. Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin-developmental effects of valproic acid. Crit Rev Toxicol 2005; 35 (8-9): 727-738. Go to original source... Go to PubMed...
    10. Wyszynski DF et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurol 2005; 64 (6): 961-965. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.